Shares of Calithera Biosciences Inc. (NASDAQ:CALA) fell 2.6% on Monday . The company traded as low as $3.33 and last traded at $3.34, with a volume of 416,242 shares traded. The stock had previously closed at $3.43.

A number of research firms have weighed in on CALA. JMP Securities reaffirmed a “buy” rating on shares of Calithera Biosciences in a research report on Wednesday, June 8th. Zacks Investment Research cut Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, May 17th. Finally, Wells Fargo & Co. reaffirmed a “buy” rating on shares of Calithera Biosciences in a research report on Thursday, May 12th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $10.38.

The stock has a 50-day moving average price of $3.51 and a 200 day moving average price of $4.90. The firm’s market capitalization is $63.31 million.

Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Tuesday, May 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.05. On average, analysts anticipate that Calithera Biosciences Inc. will post ($2.15) earnings per share for the current year.

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.